Next up......BIO Europe March 12-14 in Amsterdam. Resverlogix and Zenith are both on the schedule and both companies list the event on their respective websites as of now. Also, American College of Cardiology March 10-12 in Orlando. Resverlogix is presenting an abstract there.
Less certaintly of timeline for other events. If current estimates hold (per yesterday's slide deck) then Phase 2a kidney trial and US patient enrollment into Phase 3 BETonMACE trial begin by end of March. Maybe even throw in a Sample Size Re-estimation Analysis/Futility Analysis/DSMB report too by end of March?
